Nalm6 Human Pre-B Cell Lines Expressing Aid Or Cas9
Tech ID: 34169 / UC Case 2025-811-0
Brief Description
Innovative cell lines enabling precise genetic modifications to advance research in gene function, disease
modeling, and potential therapeutic interventions.
Full Description
This technology involves the development of Nalm6 human pre-B cell lines that have been genetically engineered to
express either activation-induced cytidine deaminase (AID) or CRISPR-associated protein 9 (Cas9). Utilizing lentiviral
transduction for the introduction of these systems, these cell lines offer a reliable platform for genetic studies,
particularly in the context of gene editing and mutation induction. The creation of these cell lines addresses the
challenge of transfecting human pre-B cells, offering an efficient and reproducible method for genetic manipulation.
Suggested uses
- Research tools for studying gene function, mutation effects, and disease mechanisms in human B cells.
- Platforms for drug discovery and development, particularly for conditions involving B cells such as certain blood
cancers.
- Diagnostic development for identifying genetic risk factors associated with B cell malignancies and other
diseases.
- Therapeutic applications, including the potential for developing gene therapy strategies targeting specific
genetic alterations in B cells.
Advantages
- Overcomes the difficulty of transfecting human pre-B cells, a significant barrier in genetic research.
- Enables precise genetic modifications using doxycycline-inducible AID or constitutively expressed Cas9.
- Facilitates the study of gene function and mutation effects with high efficiency and reproducibility.
- Potential for early detection of cancers and reduction of associated health disparities.
- Supports the development of personalized medicine approaches by enabling detailed genetic analyses.
Related Materials